Sen. Grassley Targets FDA's Handling Of Adderall XR Adverse Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Finance Committee chairman expresses concern that agency may have sought to dissuade Health Canada from suspending Adderall XR sales because "FDA could not handle another 'drug safety crisis.'" Grassley requests records of FDA's meetings with Health Canada.